McCune-Albright syndrome in adulthood

Pediatric Endocrinology Reviews

Volumn 4, Issue SUPPL. 4, 2007, Pages 453-462

  Chanson, Philippe ^a   Salenave, Sylvie ^a   Orcel, Philippe ^b  

^a BICÊTRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Acromegaly; Bisphosphonates; Fibrous dysplasia; GSP mutation; McCune Albright syndrome; Precocious puberty

Indexed keywords

ADENYLATE CYCLASE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CYCLIC AMP; GONADORELIN AGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; MEDROXYPROGESTERONE ACETATE; PAMIDRONIC ACID; PEGVISOMANT; RADIOACTIVE IODINE; RISEDRONIC ACID; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ALBRIGHT SYNDROME; ARTICLE; CAFE AU LAIT SPOT; CLINICAL FEATURE; DISEASE ASSOCIATION; FERTILITY; FIBROUS DYSPLASIA; GENE MUTATION; GONAD DYSFUNCTION; GONAD FUNCTION; HUMAN; HYPERTHYROIDISM; MULTIPLE CYCLE TREATMENT; OVULATION; PRECOCIOUS PUBERTY; SKIN PIGMENTATION;

ACROMEGALY; ADULT; FIBROUS DYSPLASIA OF BONE; FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS; PUBERTY, PRECOCIOUS;

EID: 35148886796     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Schwindinger WF, Levine MA. McCune-Albright syndrome. Trends Endocrinol Metab 1993;4:238-242
2. Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996;75:171-184
3. Collins MT, Shenker A. McCune-Albright syndrome: new insights. Curr Opin Endocrinol Diabetes 2000;6:119-125
4. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675-705
5. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune- Albright syndrome. N Engl J Med 1991;325:1688-1695
6. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992;89:5152-5156
7. Riminucci M, Fisher LW, Majolagbe A, Corsi A, Lala R, De Sanctis C, Robey PG, Bianco P. A novel GNAS1 mutation, R201G, in McCune-albright syndrome. J Bone Miner Res 1999;14:1987-1989
8. Hayward BE, Moran V, Strain L, Bonthron DT. Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally and biallelically derived proteins. Proc Natl Acad Sci USA 1998;95:15475-15480
9. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. Minireview: GNAS: normal and abnormal functions. Endocrinology 2004;145:5459-5464
10. Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A. The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 2002;87:4736-4740
11. Mantovani G, Bondioni S, Lania AG, Corbetta S, de Sanctis L, Cappa M, Di Battista E, Chanson P, Beck-Peccoz P, Spada A. Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors. J Clin Endocrinol Metab 2004;89:3007-3009
12. Lee PA, Van Dop C, Migeon CJ. McCune-Albright syndrome. Long-term follow-up. Jama 1986;256:2980-2984
13. Mauras N, Blizzard RM. The McCune-Albright syndrome. Acta Endocrinol 1986;279:207-217
14. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993;123:509-518
15. Mortensen A, Bojsen-Moller M, Rasmussen P. Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation. Two cases with a review of the literature. J Neurooncol 1989;7:25-29
16. Hall MB, Sclar AG, Gardner DF. Albright's syndrome with reactivation of fibrous dysplasia secondary to pituitary adenoma and further complicated by osteogenic sarcoma. Report of a case. Oral Surg Oral Med Oral Pathol 1984;57:616-619
17. Sevel D, James HE, Burns R, Jones KL. McCune-Albright syndrome (fibrous dysplasia) associated with an orbital tumor. Ann Ophthalmol 1984;16:283-289, 293-297
18. Heller AJ, DiNardo LJ, Massey D. Fibrous dysplasia, chondrosarcoma and McCune-Albright syndrome. Am J Otolaryngol 2001;22:297-301
19. Kaushik S, Smoker WR, Frable WJ. Malignant transformation of fibrous dysplasia into chondroblastic osteosarcoma. Skeletal Radiol 2002;31:103-106
20. Lopez-Ben R, Pitt MJ, Jaffe KA, Siegal GP. Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome. Skeletal Radid 1999;28:522-526
21. Blanco P, Schaeverbeke T, Baillet L, Lequen L, Bannwarth B, Dehais J. Chondrosarcoma in a patient with McCune-Albright syndrome. Report of a case. Rev Rhum Engl Ed 1999;66:177-179
22. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Weintroub S, Chen CC. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 2005;20:219-226
23. Laredo JD, Champsaur P. Dysplasie fibreuse des os et dysplasie ostéofibreuse. In: Laredo JD, Morvan G, Wybier M, editors. Imagerie ostéoarticulaire. Paris: Flammarion Médecine-Science 1998;p 288-301
24. Pfeffer S, Molina E, Feuillan P, Simon TR. McCune-Albright syndrome: the patterns of scintigraphic abnormalities. J Nucl Med 1990;31:1474-1478
25. Frisch LS, Copeland KC, Boepple PA. Recurrent ovarian cysts in childhood: diagnosis of McCune-Albright syndrome by bone scan. Pediatrics 1992;90:102-104
26. Hart ES, Kelly MH, Brillante B, Chen CC, Ziran N, Lee JS, Feuillan P, Leet AI, Kushner H, Robey PG, Collins MT. Onset, Progression and Plateau of Skeletal Lesions in Fibrous Dysplasia and the Relationship to Functional Outcome. J Bone Miner Res 2007 (in press)
27. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 2001;16:806-813
28. Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, Bianco P. Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. J Bone Miner Res 2003;18:1235-1246
29. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003;112:683-692
30. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 2004;19:571-577
31. Chapurlat RD, Meunier PJ. Fibrous dysplasia of bone. Baillieres Best Pract Res Ctin Rheumatol 2000;14:385-398
32. Marie P. (Cellular and molecular biology of fibrous dysplasia). Ann Pathol 2001;21:489-498
33. Marie PJ. Cellular and molecular basis of fibrous dysplasia. Histol Histopathol 2001;16:981-988
34. Marie PJ, de Pollak C, Chanson P, Lomri A. Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia. Am J Pathol 1997;150:1059-1069
35. Riminucci M, Fisher LW, Shenker A, Spiegel AM, Bianco P, Gehron Robey P. Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. Am J Pathol 1997;151:1587-1600
36. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. Lancet 1994;343:953-954
37. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous Pamidronate in fibrous dysplasia of bone. J Bone Miner Res 1997;12:1746-1752
38. Pfeilschifter J, Ziegler R. (Effect of Pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome). Med Klin 1998;93:352-359
39. Zacharin M, O'Sullivan M. Intravenous Pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 2000;137:403-409
40. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, de Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000;89:188-193
41. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ. Treatment of fibrous dysplasia of bone with intravenous Pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 2004;35:235-242
42. Chapurlat R. Current pharmacological treatment for fibrous dysplasia and perspectives for the future. Joint Bone Spine 2005;72:196-198
43. Chapurlat RD. Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 2006;21 (Suppl 2):P114-P119
44. Kaplan FS, Fallon MD, Boden SD, Schmidt R, Senior M, Haddad JG. Estrogen receptors in bone in a patient with polyostotic fibrous dysplasia (McCune-Albright syndrome). N Engl J Med 1988;319:421-425
45. Obuobie K, Mullik V, Jones C, John R, Rees AE, Davies JS, Scanlon MF, Lazarus JH. McCune-Albright syndrome: growth hormone dynamics in pregnancy. J Clin Endocrinol Metab 2001;86:2456-2458
46. Cutler CM, Lee JS, Butman JA, FitzGibbon EJ, Kelly MH, Brillante BA, Feuillan P, Robey PG, DuFresne CR, Collins MT. Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. Neurosurgery 2006;59:1011-1017; discussion 1017-1018
47. Foster CM, Comite F, Pescovitz OH, Ross JL, Loriaux DL, Cutler GB Jr. Variable response to a long-acting agonist of luteinizing hormone- releasing hormone in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 1984;59:801-805
48. Comite F, Shawker TH, Pescovitz OH, Loriaux DL, Cutler GB Jr. Cyclical ovarian function resistant to treatment with an analogue of luteinizing hormone releasing hormone in McCune-Albright syndrome. N Engl JMed 1984;311:1032-1036
49. de Sanctis C, Lala R, Matarazzo P, Balsamo A, Bergamaschi R, Cappa M, Cisternino M, de Sanctis V, Lucci M, Franzese A, Ghizzoni L, Pasquino AM, Segni M, Rigon F, Saggese G, Bertelloni S, Buzi F. McCune-Albright syndrome: a longitudinal clinical study of 32 patients. J Pediatr Endocrinol Metab 1999;12:817-826
50. Coutant R, Lumbroso S, Rey R, Lahlou N, Venara M, Rouleau S, Sultan C, Limal JM. Macroorchidism due to autonomous hyperfunction of Sertoli cells and G(s)alpha gene mutation: an unusual expression of McCune-Albright syndrome in a prepubertal boy. J Clin Endocrinol Metab 2001;86:1778-1781
51. Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C, Kenigsberg D, Loriaux DL, Cutler GB Jr. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr 1986;108:47-54
52. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986;315:1115-1119
53. Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993;77:647-651
54. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003;143:60-66
55. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome; a pilot study. J Clin Endocrinol Metab 2007;92:2100-2106
56. Nunez SB, Calis K, Cutler GB Jr, Jones J, Feuillan PP. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003;88:5730-5733
57. Pasquino AM, Tebaldi L, Cives C, Maciocci M, Boscherint B. Precocious puberty in the McCune-Albright syndrome. Progression from gonadotrophin- independent to gonadotrophin-dependent puberty in a girl. Acta Paediatr Scand 1987;76:841-843
58. Boepple PA, Frisch LS, Wierman ME, Hoffman WH, Crowley WF Jr. The natural history of autonomous gonadal function, adrenarche and central puberty in gonadotropin-independent precocious puberty. J Clin Endocrinol Metab 1992;75:1550-1555
59. Laven JS, Lumbroso S, Sultan C, Fauser BC. Dynamics of ovarian function in an adult woman with McCune-Albright syndrome. J Clin Endocrinol Metab 2001;86:2625-2630
60. Matarazzo P, Lala R andreo M, Einaudi S, Altare F, Viora E, Buzi F, De Luca F, De Sanctis V, Rigon F, Wasniewska M, de Sanctis L, de Sanctis C. McCune-Albright syndrome: persistence of autonomous ovarian hyperfunction during adolescence and early adult age. J Pediatr Endocrinol Metab 2006;19(Suppl 2):607-617
61. Malchoff CD, Reardon G, MacGillivray DC, Yamase H, Rogol AD, Malchoff DM. An unusual presentation of McCune-Albright syndrome confirmed by an activating mutation of the Gs alpha-subunit from a bone lesion. J Clin Endocrinol Metab 1994;78:803-806
62. Cavanah SF, Dons RF. McCune-Albright syndrome: how many endocrinopathies can one patient have? South Med J 1993;86:364-367
63. Happle R. The McCune-Albright syndrome: a lethal gene surviving by mosaicism. Clin Genet 1986;29:321-324
64. Laven JS, Lumbroso S, Sultan C, Fauser BC. Management of infertility in a patient presenting with ovarian dysfunction and McCune-Albright syndrome. J Clin Endocrinol Metab 2004;89:1076-1078
65. Wasniewska M, De Luca F, Bertelloni S, Matarazzo P, Weber G, Crisafulli G, Valenzise M, Lala R. Testicular microlithiasis: an unreported feature of McCune-Albright syndrome in males. J Pediatr 2004;145:670-672
66. Peterson AC, Bauman JM, Light DE, McMann LP, Costabile RA. The prevalence of testicular microlithiasis in an asymptomatic population of men 18 to 35 years old. J Urol 2001;166:2061-2064
67. Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989;68:1148-1154
68. Sherman SI, Ladenson PW. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome. J Endocrinol Invest 1992;15:185-190
69. Feuillan PP, Jones J, Ross JL. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. J Clin Endocrinol Metab 1995;80:1357-1360
70. Sakaki S, Irbkoyama S, Mamitsuka K, Nakayama M, Goto M, Kuratsu J. A case of pituitary adenoma associated with McCune-Albright syndrome. Pituitary 1999;1:297-302
71. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002;87:5104-5112
72. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994;131:229-234
73. Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, Young J, Chanson P. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J Clin Endocrinol Metab 2006;91:4957-4961
74. Pacini F, Peril G, Bagnolesi P, Cilotti A, Pinchera A. McCune-Albright syndrome with gigantism and hyperprolactinemia. J Endocrinol Invest 1987;10:417-420
75. Abs R, Beckers A, Van de Vyver FL, De Schepper A, Stevenaert A, Hennen G. Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome. J Endocrinol Invest 1990;13:671-675
76. Premawardhana LD, Vora JP, Mills R, Scanlon MF. Acromegaly and its treatment in the McCune-Albright syndrome. Clin Endocrinol (Oxf) 1992;36:605-608
77. Gessl A, Freissmuth M, Czech T, Matula C, Hainfellner JA, Buchfelder M, Vierhapper H. Growth hormone-prolactin-thyrotropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functionally normal Gs alpha protein. J Clin Endocrinol Metab 1994;79:1128-1134
78. Dotsch J, Kiess W, Hanze J, Repp R, Ludecke D, Blum WF, Rascher W. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome. J Clin Endocrinol Metab 1996;81:3839-3842
79. Toth M, Toke J, Kiss E, Bernad I, Miheller P, Szucs N, Racz K. (Acromegaly associated with McCune-Albright syndrome). Orv Hetil 2002;143:1070-1073
80. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999;84:2759-2765
81. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant (see comments). N Engl J Med 2000;342:1171-1177
82. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-1759
83. Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA, Robey PG, Collins MT. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 2006;91:2960-2966
84. Mastorakos G, Mitsiades NS, Doutas AG, Koutras DA. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997;7:433-439
85. Ferguson RE Jr, Vasconez HC. Laser treatment of congenital nevi. J Craniofac Surg 2005;16:908-914
86. Silva ES, Lumbroso S, Medina M, Gillerot Y, Sultan C, Sokal EM. Demonstration of McCune-Albright mutations in the liver of children with high gammaGT progressive cholestasis. J Hepatol 2000;32:154-158
87. Ham J, Ivan M, Wynford-Thomas D, Scanion MF. GH3 cells expressing constitutively active Gs alpha (Q227L) show enhanced hormone secretion and proliferation. Mol Cell Endocrinol 1997;127:41-47
88. Muca C, Vallar L. Expression of mutationally activated G alpha s stimulates growth and differentiation of thyroid FRTL5 cells. Oncogene 1994;9:3647-3653
89. Lania A, Mantovani G, Spada A. G protein mutations in endocrine diseases. Eur J Endocrinol 2001;145:543-559
90. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-3099
91. Suarez HG. Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol (Oxf) 1998;48:531-546
92. Collins MT, Sarlis NJ, Merino MJ, Monroe J, Crawford SE, Krakoff JA, Guthrie LC, Bonat S, Robey PG, Shenker A. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab 2003;88:4413-4417
93. Yang GC, Yao JL, Feiner HD, Roses DF, Kumar A, Mulder JE. Lipid-rich follicular carcinoma of the thyroid in a patient with McCune-Albright syndrome. Mod Pathol 1999;12:969-973
94. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 2004;25:102-152
95. Huvos AG, Higinbotham NL, Miller TR. Bone sarcomas arising in fibrous dysplasia. J Bone Joint Surg Am 1972;54:1047-1056
96. Mock D, Rosen IB. Osteosarcoma in irradiated fibrous dysplasia. J Oral Pathol 1986;15:1-4
97. Present D, Bertoni F, Enneking WF. Osteosarcoma of the mandible arising in fibrous dysplasia. A case report. Clin Orthop Relat Res 1986:238-244
98. Taconis WK. Osteosarcoma in fibrous dysplasia. Skeletal Radiol 1988;17:163-170
99. Ruggieri P, Sim FH, Bond JR, Unni KK. Malignancies in fibrous dysplasia. Cancer 1994;73:1411-1424
100. Hansen MR, Moffat JC. Osteosarcoma of the Skull Base after Radiation Therapy in a Patient with McCune-Albright Syndrome: Case Report. Skull Base 2003;13:79-83
101. Jhala DN, Eltoum I, Carroll AJ, Lopez-Ben R, Lopez-Terrada D, Rao PH, Pettenati MJ, Siegal GP. Osteosarcoma in a patient with McCune-Albright syndrome and Mazabrauds syndrome: a case report emphasizing the cytological and cytogenetic findings. Hum Pathol 2003;34:1354-1357
102. Shenker A, Chanson P, Weinstein LS, Chi P, Spiegel AM, Lomri A, Marie PJ. Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet 1995;4:1675-1676
103. Pollandt K, Engels C, Kaiser E, Werner M, Delling G. Gsalpha gene mutations in monostotic fibrous dysplasia of bone and fibrous dysplasia-like low-grade central osteosarcoma. Virchows Arch 2001;439:170-175
104. Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M. A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to Gsalpha mutation at the Arg201 codon: polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-embedded tissues. J Mol Diagn 2000;2:67-72
105. Sheppard DG, Libshitz HI. Post-radiation sarcomas: a review of the clinical and imaging features in 63 cases. Clin Radiol 2001;56:22-29
106. Huston TL, Simmons RM. Ductal carcinoma in situ in a 27-year-old woman with McCune-Albright syndrome. Breast J 2004;10:440-442
107. Tanabeu Y, Nakahara S, Mitsuyama S, Ono M, Toyoshima S. Breast Cancer in a Patient with McCune-Albright Syndrome. Breast Cancer 1998;5:175-178